Back to Top Skip to main content

Prevalence of Glucose-6-Phosphate Dehydrogenase Deficiency, U.S. Armed Forces, May 2004–September 2018

Staff Sgt. Cory Gage, 23d Medical Support Squadron medical laboratory technician, places a blood specimen in an automated hematology analyzer, Aug. 29, 2017, at Moody Air Force Base, Ga. Moody’s lab technicians process blood to check for a variety of cell abnormalities from infections to cancer. (U.S. Air Force photo by Airman 1st Class Erick Requadt) Staff Sgt. Cory Gage, 23d Medical Support Squadron medical laboratory technician, places a blood specimen in an automated hematology analyzer, Aug. 29, 2017, at Moody Air Force Base, Ga. Moody’s lab technicians process blood to check for a variety of cell abnormalities from infections to cancer. (U.S. Air Force photo by Airman 1st Class Erick Requadt)

Recommended Content:

Medical Surveillance Monthly Report

ABSTRACT

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an inherited genetic disorder most commonly associated with hemolytic anemia. Among those with G6PD deficiency, hemolytic anemia may be triggered by bacterial or viral infections and by certain foods and drugs, including the 8-aminoquinoline (8-AQ) class of antimalarials. Because 8-AQ drugs remain the only drugs approved by the U.S. Food and Drug Administration for malaria relapse prevention, the Department of Defense (DoD) requires testing of all service members’ G6PD status. To estimate prevalence of G6PD deficiency among DoD service members, Composite Health Care System-generated, Health Level 7-formatted laboratory records for all service members (n=2,311,223) dated between May 2004 and September 2018 were queried for G6PD testing. Corresponding demographic data were obtained from the Defense Enrollment Eligibility Reporting System. Overall prevalence of G6PD deficiency among this cohort was low, at 2.2%. Demographic trends mirrored U.S. statistics; the cohort prevalence among males (2.3%) was higher than among females (1.5%), and the prevalence among non-Hispanic blacks (9.5%) was higher than among those in any other race/ethnicity group.

WHAT ARE THE NEW FINDINGS?    

Test results for 2,311,223 active duty service members over a 14-year period confirmed previous service-specific surveillance reports about the prevalence of G6PD deficiency. The deficiency was found in 2.2% of all service members, and the prevalence ranged from 11.2% among non-Hispanic black males to 0.3% among non-Hispanic white females. To the authors’ knowledge, this is the first DoD report widely addressing the prevalence of G6PD deficiency among active duty service members.

WHAT IS THE IMPACT ON READINESS AND FORCE HEALTH PROTECTION?

Service members who travel or deploy to malaria-endemic regions are at risk of malaria infection. Because of the risk of hemolytic anemia from use of the 8-AQ class of antimalarial drugs (e.g., primaquine, tafenoquine), military leaders should be aware of G6PD deficiency diagnoses among service members under their purview and should continue adherence to current DoD G6PD screening policies.

BACKGROUND

Glucose-6-phosphate dehydrogenase (G6PD) is an essential enzyme for the pentose phosphate pathway in the erythrocyte because it converts glucose-6-phosphate to 6-phosphoglucono-d-lactone. G6PD also converts nicotinamide adenine dinucleotide phosphate (NADP) to the reduced form of NADP (NADPH), a critical redox-active cofactor that mitigates oxidative damage to the erythrocytes.G6PD deficiency is a genetic condition arising from mutations on the Gd gene on the X chromosome that encodes G6PD enzyme. As an X-linked recessive genetic disorder, G6PD deficiency has a higher prevalence in males than females.1 Reduced G6PD activity in G6PD deficient individuals can cause hemolysis with different manifestations (e.g., kernicterus in infants and hemolytic crises) from exposures to oxidative stressors including certain medications, fava beans, and infections.1,2 For example, members of the 8-aminoquinoline (8-AQ) class of antimalarial drugs can cause hemolysis in the G6PD deficient population. 

8-AQ class antimalarial drugs (primaquine and the newly Food and Drug Administration (FDA)-approved tafenoquine for weekly chemoprophylaxis and single-dose radical cure) are important because they target hypnozoites—a dormant form of the malaria parasite common in Plasmodium vivax and P. ovale infections that can emerge from the liver and cause relapse days to years after treatment has cleared the malaria parasites from the circulating red blood cells. Although these infections are less often fatal than P. falciparum infections, they still can cause significant morbidity because of relapse from the dormant form of the parasites. Because the 8-AQ class drugs are the only FDA-approved drugs for malaria relapse prevention, the Department of Defense (DoD) mandated G6PD testing of service members at the time of military accession as early as 1981 (Instruction 6465.13,4 updated with DoD Instruction 6465.015 in 2015 and 6025.146 in 2018), and the Army implemented additional G6PD screening of soldiers deploying to malaria endemic regions as early as 2004.7 However, given that this drug class may trigger hemolytic anemia among those who are G6PD deficient, it is important to adhere to DoD G6PD screening instructions and provide results to command leaders and tested individuals for situational awareness and force protection.

Thus, the objectives of this surveillance report are to describe the prevalence of G6PD deficiency among active duty DoD service members who were screened during 2004–2018 and remind the DoD medical community to consider the risk of hemolytic anemia when prescribing the use of the 8-AQ class of antimalarial drugs.

METHODS

This cross-sectional study used Composite Health Care System-generated, Health Level 7-formatted chemistry laboratory records from 01 May 2004 through 30 September 2018 and queried for G6PD laboratory test results among all active duty, recruit, and active reserve DoD service members tested at fixed military treatment facilities (MTFs). Generally, G6PD testing occurs during accession (recruit training), which is reflected in over 90% of these records.

Key terms used to identify G6PD assays were “G6” or “glucose 6” in the test ordered or test name fields. G6PD tests are often run in panels with other genetic and hemoglobin tests. Records were excluded from the analysis if the test name field contained text indicating other genetic testing (e.g., “sickle cell anemia”), “red blood count,” “hemoglobin testing,” “miscellaneous,” or if the test type could not be determined.

G6PD laboratory test result fields were alpha character–based or numeric. Character-based records with a test result of “Not Deficient,” “High,” or “Normal” were classified as “Not Deficient.” Records with a test result of “Deficient” or “Low” were classified as “Deficient.” Because of laboratory testing variations between MTFs, numeric test results were classified based upon the reference ranges indicated in the record. If a record had no reference range but units of measure were noted, the reference range was inferred based on other tests with the same unit of measure. In an effort to provide an accurate denominator, if the test result was numeric and the units of measure and the reference ranges could not be extrapolated from the data, the record result was classified as “Unknown.” To avoid misclassification of results, if the test result field referred to the free-text result notes field, the record was classified as “Unknown.”

If a service member had more than 1 record and the test results differed, the records were prioritized as follows: a “Deficient” record was retained over a “Not Deficient” or “Unknown” record, and a “Not Deficient” record was retained over an “Unknown” record. Only 1 record per service member was retained for analysis.

Final records were matched to the most recent Defense Enrollment Eligibility Reporting System (DEERS) record for each service member to obtain race/ethnicity and service affiliation. Records were not included in the final dataset if there were no matching DEERS records (n=29,642). Demographic frequencies and distributions for the final cohort were calculated using SAS software, version 9.4 (SAS Institute, Cary, NC).

RESULTS

Overall results are presented in Table 1. G6PD laboratory test results for 2,311,223 service members were evaluated. Examination of laboratory records indicated that the vast majority (97.7%) of service members tested were not G6PD deficient. Only 0.13% of all records could not be classified. The majority of service members represented in this analysis (89.5%) had 1 record for G6PD testing, 8.7% had 2 records, and the remaining 1.8% had 3 or more records (data not shown). Of those with more than 1 record where the classification changed, the following changes were observed: “Not Deficient” to “Deficient” (4.6%), “Unknown” to “Deficient” (3.7%), and “Unknown” to “Not Deficient” (91.7%) (data not shown).

Of the 2,311,223 service members identified in the laboratory records as having been tested, 83.3% were male and 16.7% were female. Sex was not indicated in 3,070 records (0.13%). Males were more likely to be classified as G6PD deficient (2.3%) than females (1.5%).

Race/ethnicity was classified as “other/unknown” in 3.0% of all records (Table 1). Non-Hispanic blacks were most likely to be classified as G6PD deficient (9.5%), followed by Asians/Pacific Islanders (2.9%) and Hispanics (1.5%). Non-Hispanic whites were the least likely to be classified as G6PD deficient (0.4%).

The G6PD classifications stratified by race/ethnicity and sex are shown in Table 2. Among males, non-Hispanic black service members were the most likely to be classified as G6PD deficient (11.2%), followed by Asian/Pacific Islander and Hispanic service members (3.3% and 1.7%, respectively). Non-Hispanic black males were more than twice as likely as non-Hispanic black females (4.7%) to be classified as G6PD deficient. Non-Hispanic black females had the highest proportion of G6PD deficiency of all female race/ethnicity groups. Although the non-Hispanic white race/ethnicity group represented the largest proportion of service members tested (59.8%), males and females in this race/ethnicity group were least likely to be G6PD deficient (0.4% and 0.3%, respectively).

Table 3 illustrates the G6PD results by service. The proportions of service members who tested positive for G6PD deficiency were broadly similar among the services. The Army had the highest percentage of service members with G6PD deficiency (2.7%), followed by the Air Force (2.3%) and Navy (2.2%). The Coast Guard (1.2%) and the Marine Corps (1.1%) had the lowest rates of service members with G6PD deficiency.

EDITORIAL COMMENT

The current study found an overall G6PD deficiency prevalence rate of 2.2% (n=49,897) among the 2,311,223 active and reserve component service members with laboratory results. To the authors’ knowledge, this is the largest study of G6PD deficiency screening among DoD service members. The results of the current analysis are consistent with other studies that have found that non-Hispanic black males are more likely to be G6PD deficient than any other race/ethnicity group.7–10

Before adoption of the newly FDA-approved tafenoquine as the primary force health protection measure for DoD service members against malaria infection, it is critical to understand the indications for prevention and treatment as well as the limitations.11 Regardless of an improved drug performance, including a radical curative efficacy, longer drug half-life, and once-weekly dosing regimen, tafenoquine still retains the risk of inducing hemolytic anemia in G6PD deficient individuals.

The results of this study must be interpreted within the context of several limitations. Laboratory records queried for this analysis were derived from fixed MTFs and do not include records from in-theater, shipboard, battalion aid station, or Purchased CareThe TRICARE Health Program is often referred to as purchased care. It is the services we “purchase” through the managed care support contracts.purchased care providers, although inclusion of these records, were they available, would not be expected to alter the findings presented herein. Genetic testing is generally performed during the accession phase of military service, so very few tests would need to be performed at austere or remote locations. Although validation steps were taken to avoid misclassification, it is possible that some results were misclassified. Because less than 1.0% of all records were classified as “Unknown,” it is unlikely that these results would change the overall prevalence rates. Final laboratory records were matched to the most recent DEERS record for each service member; a service member may have changed service affiliation after the laboratory testing, but this practice is uncommon. Additionally, laboratory data were derived from DoD service members and may not be generalizable to a larger U.S. civilian population.

Given the findings of the current analysis, DoD healthcare providers, Combatant Commanders, and their command surgeons in areas of responsibility that include malaria-endemic regions should remain aware of the risks of 8-AQ hemolytic anemia in G6PD deficient service members. In addition, targeted health education and risk management instruction should be provided to G6PD deficient service members in order to mitigate adverse health outcomes. Furthermore, continued implementation of the DoD’s G6PD screening instruction is required to mitigate G6PD deficiency-associated adverse events.

 

Author affiliations: Malaria Vaccine Branch, Walter Reed Army Institute of Research, Silver Spring, MD (MAJ Jangwoo Lee); Defense Health Agency, Combat Support, Healthcare Operations, Public Health Division, Armed Forces Health Surveillance Branch, Navy Satellite (Beth T. Poitras)

Acknowledgments: The authors thank LTC Chad C. Black, LTC Mara Kreishman-Deitrick, COL James E. Moon, COL Viseth Ngauy, MAJ Brandon S. Pybus, and Angela D. Schlein for their support of this analysis and report.

Disclaimer: The views expressed in this report are those of the authors and do not necessarily reflect the official policy or position of the Armed Forces Health Surveillance Branch, the Defense Health Agency, the Department of the Army, the Department of the Navy, the Department of Defense, or the U.S. Government. Analytic support was provided by the Armed Forces Health Surveillance Branch of the Public Health Division at the Defense Health Agency. Authors are employees of the U.S. Government. This work was prepared as part of their official duties. Title 17, U.S.C., §105 provides that copyright protection under this title is not available for any work of the U.S. Government. Title 17, U.S.C., §101 defines a U.S. Government work as a work prepared by a military service member or employee of the U.S. Government as part of that person’s official duties.


REFERENCES

1. Richardson SR, O'Malley GF. (2019). Glucose 6 phosphate dehydrogenase (G6PD) deficiency. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK470315/. Accessed 23 January 2019.

2. Luzzatto L, Arese P. Favism and glucose-6-phosphate dehydrogenase deficiency. N Eng J Med. 2018;378(1):60–71.

3. Department of Defense Instruction 6465.1. Hemoglobin S and erythrocyte glucose-6-phosphate dehydrogenase deficiency test program. 29 July 1981.

4. Webber BJ, Witkop CT. Screening for sickle-cell trait at accession to the United States military. Mil Med. 2014;179(11):1184–1189.

5. Department of Defense Instruction 6465.01. Erythrocyte glucose-6-phosphate dehydrogenase deficiency (G6PD) and sickle cell trait screening programs. 17 July 2015.

6. Department of Defense Instruction 6025.14. Active duty service members (ADSM) erythrocyte glucose-6-phosphate dehydrogenase (G6PD) deficiency and sickle cell trait (SCT) screening. 6 December 2018.

7. Chinevere TD, Murray CK, Grant E Jr, Johnson GA, Duelm F, Hospenthal DR. Prevalence of glucose-6-phosphate dehydrogenase deficiency in U.S. Army personnel. Mil Med. 2006;171(9):905–907.

8. Heller P, Best WR, Nelson RB, Becktel J. Clinical implications of sickle-cell trait and glucose-6-phosphate dehydrogenase deficiency in hospitalized black male patients. N Eng J Med. 1979;300(18):1001–5.

9. Tarlov AR, Brewer GJ, Carson PE, Alving AS. Primaquine sensitivity. Glucose-6-phosphate dehydrogenase deficiency: an inborn error of metabolism of medical and biological significance. Arch Intern Med. 1962;109:209–234.

10. Uddin DE, Dickson LG, Brodine CE. Glucose-6-phosphate dehydrogenase deficiency in military recruits. JAMA. 1974;227(12):1408–1409.

11. Fukuda M, Wojnarski M, Martin N, Zottig V, Waters NC. Editorial: Malaria in the Korean Peninsula: risk factors, latent infections, and the possible role of tafenoquine, a new antimalarial weapon. MSMR. 2018;25(11):2–3.

Results of G6PD deficiency laboratory testing among active duty DoD service members, 2004–2018

Classification of G6PD laboratory records among active duty DoD service members, by race/ethnicity and sex, 2004–2018

Classification of G6PD laboratory records among active duty DoD service members, by service, 2004–2018

You also may be interested in...

Ambulatory Visits, Active Component, U.S. Armed Forces, 2017

Infographic
5/23/2018
ACTIVE COMPONENT, U.S. ARMED FORCES, 2017  This report documents the frequencies, rates, trends, and characteristics of ambulatory healthcare visits of active component members of the U.S. Army, Navy, Air Force, and Marine Corps.

ACTIVE COMPONENT, U.S. ARMED FORCES, 2017 This report documents the frequencies, rates, trends, and characteristics of ambulatory healthcare visits of active component members of the U.S. Army, Navy, Air Force, and Marine Corps.

Recommended Content:

Health Readiness | Epidemiology and Analysis | Medical Surveillance Monthly Report

Morbidity Burdens Attributable to Various Illnesses and Injuries, Deployed Active and Reserve Component Service Member, U.S. Armed Forces, 2017

Infographic
5/23/2018
Morbidity Burdens Attributable to Various Illnesses and Injuries, Deployed Active and Reserve Component Service Member, U.S. Armed Forces, 2017

Recommended Content:

Health Readiness | Epidemiology and Analysis | Medical Surveillance Monthly Report

Absolute and Relative Morbidity Burdens, Attributable to Various Illnesses and Injuries, 2017

Infographic
5/23/2018
Absolute and Relative Morbidity Burdens, Attributable to Various Illnesses and Injuries, 2017

Recommended Content:

Health Readiness | Armed Forces Health Surveillance Branch | Epidemiology and Analysis | Medical Surveillance Monthly Report

Hospitalizations, Active Component, U.S. Armed Forces, 2017

Infographic
5/23/2018
This report documents the frequencies, rates, trends, and distributions of hospitalizations of active component members of the U.S. Army, Navy, Air Force, and Marine Corps during calendar year 2017.

This report documents the frequencies, rates, trends, and distributions of hospitalizations of active component members of the U.S. Army, Navy, Air Force, and Marine Corps during calendar year 2017.

Recommended Content:

Health Readiness | Epidemiology and Analysis | Medical Surveillance Monthly Report

Heat Illness

Infographic
4/13/2018
Exertional, or exercise-associated, hyponatremia refers to a low serum, plasma, or blood sodium concentration (below 135 milliequivalents/liter) that develops during or up to 24 hours following prolonged physical activity.

There were a total of 2,163 incident cases of heat illness among active component service members, including 464 cases of heat stroke and 1,699 cases of heat exhaustion.

Recommended Content:

Health Readiness | Epidemiology and Analysis | Medical Surveillance Monthly Report

Rhabdomyolysis

Infographic
4/13/2018
Rhabdomyolysis

Recommended Content:

Health Readiness | Epidemiology and Analysis | Medical Surveillance Monthly Report

Hyponatremia

Infographic
4/13/2018
Exertional, or exercise-associated, hyponatremia refers to a low serum, plasma, or blood sodium concentration (below 135 milliequivalents/liter) that develops during or up to 24 hours following prolonged physical activity.

Exertional, or exercise-associated, hyponatremia refers to a low serum, plasma, or blood sodium concentration (below 135 milliequivalents/liter) that develops during or up to 24 hours following prolonged physical activity.

Recommended Content:

Health Readiness | Epidemiology and Analysis | Medical Surveillance Monthly Report

Cardiovascular Diseases

Infographic
4/4/2018
At the time of entry into military service, many members of the U.S. Armed Forces are young, physically active, and in good physical health. However, following entry, many service members develop or are discovered to have risk factors for cardiovascular disease (CVD). This report documents the incidence and prevalence of select risk factors for CVD among active component (AC) service members and provides estimates of the incidence rates of major categories of cardiovascular diseases themselves.

At the time of entry into military service, many members of the U.S. Armed Forces are young, physically active, and in good physical health. However, following entry, many service members develop or are discovered to have risk factors for cardiovascular disease (CVD). This report documents the incidence and prevalence of select risk factors for CVD among active component (AC) service members and provides estimates of the incidence rates of major categories of cardiovascular diseases themselves.

Recommended Content:

Health Readiness | Epidemiology and Analysis | Medical Surveillance Monthly Report

Mental Health Problems

Infographic
4/4/2018
This report summarizes the numbers, natures, and rates of incident mental health disorder diagnoses as well as mental health problems among active component U.S. service members during 2007–2016.

This report summarizes the numbers, natures, and rates of incident mental health disorder diagnoses as well as mental health problems among active component U.S. service members during 2007–2016.

Recommended Content:

Health Readiness | Armed Forces Health Surveillance Branch | Epidemiology and Analysis | Medical Surveillance Monthly Report

Surveillance for Vector-Borne Diseases, Active and Reserve Component Service Members, U.S. Armed Forces, 2010 – 2016

Infographic
2/14/2018
Within the U.S. Armed Forces considerable effort has been applied to the prevention and treatment of vector-borne diseases. A key component of that effort has been the surveillance of vector-borne diseases to inform the steps needed to identify where and when threats exist and to evaluate the impact of preventive measures. This report summarizes available health records information about the occurrence of vector-borne infectious diseases among members of the U.S. Armed Forces, during a recent 7-year surveillance period. For the 7-surveillance period, there were 1,436 confirmed cases of vector-borne diseases, 536 possible cases, and 8,667 suspected cases among service members of the active and reserve components. •	“Confirmed” case = confirmed reportable medical event. •	“Possible” case = hospitalization with a diagnosis for a vector-borne disease. •	“Suspected” case = either a non-confirmed reportable medical event or an outpatient medical encounter with a diagnosis of a vector-borne disease. Lyme disease (n=721) and malaria (n=346) were the most common diagnoses among confirmed and possible cases. •	In 2015, the annual numbers of confirmed case of Lyme disease were the fewest reported during the surveillance period. •	Diagnoses of Chikungunya (CHIK) and Zika (ZIKV) were elevated in the years following their respective entries into the Western Hemisphere: CHIK (2014 and 2015); ZIKV (2016). The available data reinforce the need for continued emphasis on the multidisciplinary preventive measures necessary to counter the ever-present threat of vector-borne disease. Access the full report in the February 2018 MSMR (Vol. 25, No. 2). Go to www.Health.mil/MSMR  Background graphic shows service member in the field and insects which spread vector borne diseases.

This infographic summarizes available health records information about the occurrence of vector-borne infectious diseases among members of the U.S. Armed Forces, during a recent 7-year surveillance period (2010 – 2016).

Recommended Content:

Health Readiness | Epidemiology and Analysis | Medical Surveillance Monthly Report | Preventing Mosquito-Borne Illnesses | Chikungunya | Malaria | Zika Virus

Malaria U.S. Armed Forces, 2017

Infographic
2/14/2018
Since 1999, the Medical Surveillance Monthly Report (MSMR) has published periodic updates on the incidence of malaria among U.S. service members. Malaria infection remains an important health threat to U.S. service members, who are located in endemic areas because of long-term duty assignments, participation in shorter-term contingency operations, or personal travel. This update for 2017 describes the epidemiologic patterns of malaria incidence in active and reserve component service members of the U.S. Armed Forces. Findings •	A total of 32 service members were diagnosed with or reported to have malaria, which is the lowest number of cases in any given year during the 10-year surveillance period. •	Health records documented the performance of laboratory tests for malaria for 22 of the cases. The tests for 17 of the 22 were positive for malaria ( stick figure graphic visually depicts this information). •	In 2017, 75.0% (24 of 32) of malaria cases among U.S. service members were diagnosed during May – October (calendar graphic showing the months visually). •	Of the 32 malaria cases in 2017, more than 1/3 of the infections were considered to have been acquired in Africa. Two bar charts display the following information: •	Bar chart 1: Numbers of malaria cases by Plasmodium species and calendar year of diagnosis/report, active and reserve components, U.S. Armed Forces, 2008 – 2017  •	Bar chart 2: Annual numbers of cases of malaria associated with specific locations of acquisition, active and reserve components, U.S. Armed Forces, 2008 – 2017  The majority of U.S. military members diagnosed with malaria in 2017 were: •	Male (96.9%) •	Active component (81.3%) •	In the Army (75.0%) •	In their 20’s (56.3%) Access the full report in the February 2018 MSMR (Vol. 25 No. 2). Go to www.Health.mil/MSMR  Picture of a mosquito displays on the graphic.

This update for 2017 describes the epidemiologic patterns of malaria incidence in active and reserve component service members of the U.S. Armed Forces.

Recommended Content:

Health Readiness | Armed Forces Health Surveillance Branch | Epidemiology and Analysis | Medical Surveillance Monthly Report

Department of Defense Global, Laboratory-based Influenza Surveillance Program’s Influenza vaccine effectiveness estimates and surveillance trends, 2016 – 2017 Influenza Season

Infographic
2/5/2018
Each year, the Department of Defense (DoD) Global, Laboratory-based Influenza Surveillance Program performs surveillance for influenza among service members of the DoD and their dependent family members. In addition to routine surveillance, vaccine effectiveness (VE) studies are performed and results are shared with the Food and Drug Administration, Centers for Disease Control and Prevention, and the World Health Organization for vaccine evaluation. This report documents the annual surveillance trends for the 2016 – 2017 influenza season and the end-of-season VE results. The analysis was performed by the U.S. Air Force School of Aerospace Medicine Epidemiology Laboratory, and the DoD Influenza Surveillance Program staff at Wright-Patterson Air Force Base, OH. FINDINGS: A total of 5,555 specimens were tested from 84 locations: •	2,486 (44.7%) negative •	1,382 (24.9%) influenza A •	1,093 (19.7%) other respiratory pathogens •	443 (8.0%) influenza B •	151 (2.7%) co-infections The predominant influenza strain was A (H3N2), representing 73.8% of all circulating influenza. Pie chart displays this information. Graph showing the numbers and percentages of respiratory specimens positive for influenza viruses, and numbers of influenza viruses identified, by type, by surveillance week, Department of Defense healthcare beneficiaries, 2016 – 2017 influenza season displays. The vaccine effectiveness (VE) for this season was slightly lower than for the 2015 – 2016 season, which had a 63% (95% confidence interval: 53% - 71%) adjusted VE. The adjusted VE for the 2016 – 2017 season was 48% protective against all types of influenza.  Access the full report in the January 2018 MSMR (Vol. 25, No. 1). Go to: www.Health.mil/MSMR

This infographic documents the annual surveillance trends for the 2016 – 2017 influenza season and the end-of-season vaccine effectiveness.

Recommended Content:

Health Readiness | Influenza Summary and Reports | Medical Surveillance Monthly Report | Vaccine-Preventable Diseases | Force Health Protection | Global Health Engagement

Outbreak of Influenza and Rhinovirus co-circulation among unvaccinated recruits, U.S. Coast Guard Training Center Cape May, NJ, 24 July – 21 August 2016

Infographic
2/5/2018
On 29 July 2016, the U.S. Coast Guard Training Center Cape May (TCCM), NJ, identified an increase in febrile respiratory illness (FRI) among recruits who were unvaccinated against seasonal influenza as a result of the annual vaccine’s expiration. This report characterizes the outbreak and containment measures implemented at TCCM during the outbreak period. In 2016, respiratory infections affected more than 250,000 U.S. service members and comprised approximately 22% of medical encounters among military recruit populations – who are highly susceptible to respiratory infections. Seasonal influenza and rhinovirus are two of the leading respiratory pathogens. During the Surveillance Period: 115 recruits reported respiratory infection symptoms. Pie chart 1 shows the following data: •	41 (35.7%) suspected cases •	74 (64.3%) confirmed cases Among confirmed cases, lab specimens tested positive for: •	Influenza A 34 (45.9%) •	Rhinovirus 28 (37.8%) •	Influenza A and rhinovirus co-infection 11 (14.9%) •	Rhinovirus and adenovirus co-infection 1 (1.4%) Data above depicted in pie chart 2. •	24 July – 6 August, Influenza predominated •	7 August – 20 August, Rhinovirus predominated Although the outbreak significantly affected operations at TCCM, a timely and comprehensive response resulted in containment of the outbreak within 5 weeks. Key Factor for Outbreak Control •	Rapid detection through FRI sentinel surveillance •	Quick decision-making •	Streamlined response by using a single chain of command •	Rapid implementation of both nonpharmaceutical and pharmaceutical interventions Access the full report in the January 2018 MSMR (Vol. 25, No. 1). Go to: www.Health.mil/MSMR

This report characterizes the outbreak and containment measures implemented at the U.S. Coast Guard Training Center Cape May (TCCM), New Jersey, during a July 24 – August 21, 2016 outbreak period.

Recommended Content:

Health Readiness | Medical Surveillance Monthly Report | Integrated Biosurveillance | Influenza Summary and Reports

Insomnia and motor vehicle accident-related injuries, Active Component, U.S. Armed Forces, 2007 – 2016

Infographic
1/25/2018
Insomnia is the most common sleep disorder in adults and its incidence in the U.S. Armed Forces is increasing. A potential consequence of inadequate sleep is increased risk of motor vehicle accidents (MVAs). MVAs are the leading cause of peacetime deaths and a major cause of non-fatal injuries in the U.S. military members. To examine the relationship between insomnia and motor vehicle accident-related injuries (MVAs) in the U.S. military, this retrospective cohort study compared 2007 – 2016 incidence rates of MVA-related injuries between service members with diagnosed insomnia and service members without a diagnosis of insomnia. After adjustment for multiple covariates, during 2007 – 2016, active component service members with insomnia had more than double the rate of MVA-related injuries, compared to service members without insomnia. Findings:  •	Line graph shows the annual rates of motor vehicle accident-related injuries, active component service members with and without diagnoses of insomnia, U.S. Armed Forces, 2007 – 2016  •	Annual rates of MVA-related injuries were highest in the insomnia cohort in 2007 and 2008, and lowest in 2016 •	There were 5,587 cases of MVA-related injuries in the two cohorts during the surveillance period. •	Pie chart displays the following data: 1,738 (31.1%) in the unexposed cohort and 3,849 (68.9%) in the insomnia cohort The highest overall crude rates of MVA-related injuries were seen in service members who were: •	Less than 25 years old •	Junior enlisted rank/grade •	Armor/transport occupation •	 •	With a history of mental health diagnosis •	With a history of alcohol-related disorders Access the full report in the December 2017 (Vol. 24, No. 12). Go to www.Health.mil/MSMR Image displays a motor vehicle accident.

To examine the relationship between insomnia and motor vehicle accident-related injuries (MVAs) in the U.S. military, this retrospective cohort study compared 2007 – 2016 incidence rates of MVA-related injuries between service members with diagnosed insomnia and service members without a diagnosis of insomnia.

Recommended Content:

Armed Forces Health Surveillance Branch | Health Readiness | Medical Surveillance Monthly Report

Seizures among Active Component service members, U.S. Armed Forces, 2007 – 2016

Infographic
1/25/2018
This retrospective study estimated the rates of seizures diagnosed among deployed and non-deployed service members to identify factors associated with seizures and determine if seizure rates differed in deployment settings. It also attempted to evaluate the associations between seizures, traumatic brain injury (TBI), and post-traumatic stress disorder (PTSD) by assessing correlations between the incidence rates of seizures and prior diagnoses of TBI and PTSD. Seizures have been defined as paroxysmal neurologic episodes caused by abnormal neuronal activity in the brain. Approximately one in 10 individuals will experience a seizure in their lifetime. Line graph 1: Annual crude incidence rates of seizures among non-deployed service members, active component, U.S. Armed Forces data •	A total of 16,257 seizure events of all types were identified among non-deployed service members during the 10-year surveillance period. •	The overall incidence rate was 12.9 seizures per 10,000 person-years (p-yrs.) •	There was a decrease in the rate of seizures diagnosed in the active component of the military during the 10-year period. Rates reached their lowest point in 2015 – 9.0 seizures per 10,000 p-yrs. •	Annual rates were markedly higher among service members with recent PTSD and TBI diagnoses, and among those with prior seizure diagnoses. Line graph 2: Annual crude incidence rates of seizures by traumatic brain injury (TBI) and recent post-traumatic stress disorder (PTSD) diagnosis among non-deployed active component service members, U.S. Armed Forces •	For service members who had received both TBI and PTSD diagnoses, seizure rates among the deployed and the non-deployed were two and three times the rates among those with only one of those diagnoses, respectively. •	Rates of seizures tended to be higher among service members who were: in the Army or Marine Corps, Female, African American, Younger than age 30, Veterans of no more than one previous deployment, and in the occupations of combat arms, armor, or healthcare Line graph 3: Annual crude incidence rates of seizures diagnosed among service members deployed to Operation Enduring Freedom, Operation Iraqi Freedom, or Operation New Dawn, U.S. Armed Forces, 2008 – 2016  •	A total of 814 cases of seizures were identified during deployment to operations in Iraq and Afghanistan during the 9-year surveillance period (2008 – 2016). •	For deployed service members, the overall incidence rate was 9.1 seizures per 10,000 p-yrs. •	Having either a TBI or recent PTSD diagnosis alone was associated with a 3-to 4-fold increase in the rate of seizures. •	Only 19 cases of seizures were diagnosed among deployed individuals with a recent PTSD diagnosis during the 9-year surveillance period. •	Overall incidence rates among deployed service members were highest for those in the Army, females, those younger than age 25, junior enlisted, and in healthcare occupations. Access the full report in the December 2017 MSMR (Vol. 24, No. 12). Go to www.Health.mil/MSMR

This infographic documents a retrospective study which estimated the rates of seizures diagnosed among deployed and non-deployed service members to identify factors associated with seizures and determine if seizure rates differed in deployment settings. The study also evaluated the associations between seizures, traumatic brain injury (TBI), and post-traumatic stress disorder (PTSD) by assessing correlations between the incidence rates of seizures and prior diagnoses of TBI and PTSD.

Recommended Content:

Health Readiness | Posttraumatic Stress Disorder | Armed Forces Health Surveillance Branch | Medical Surveillance Monthly Report
<< < 1 2 3 4 > >> 
Showing results 46 - 60 Page 4 of 4

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.